Default company panoramic image
0b6c14d3 8c10 4f99 b3fc 8561f7f79fa8

MedVax Technologies, Inc.

MedVax Technologies, Inc. is a bio-pharmaceutical company developing vaccines in human clinical trials to treat or prevent cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Miami, FL, USA
  • Currency USD
  • Founded June 2010
  • Employees 6
  • Website medvax.net

Company Summary

MedVax Technologies, Inc. is a private biopharmaceutical company developing and commercializing immunotherapeutic treatments. MedVax’s portfolio includes an autologous Adenovirus P53 dendritic cell vaccine in two FDA Phase II clinical trials, in Small Cell Lung Cancer, and Breast Cancer. Medvax also has a chimeric HER2 Peptide vaccine that is concluding a 2nd Phase I trial, and preparing for a phase II trial.

Team

  • Default avatar
    Robert Brooks
    Chairman and CEO

  • Default avatar
    Robert Brooks
    Chairman and CEO